Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...

Revenue of approximately $165.0 million for the three months ended December 31, 2024, representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period.

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...

PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up well ...